Gilead Sciences' unit Kite Pharma said on Thursday it will acquire privately-held biotech firm Interius BioTherapeutics for ...

Gilead Needs Insurers to Cover New HIV Prevention Shot. CVS Isn’t Paying. Executives at Gilead Sciences, the biotech behind a ...

Gilead Sciences (($CC:GILD.CUR)) announced an update on their ongoing clinical study. Gilead Sciences, in collaboration ...

The deal gives Gilead ownership of a technology that can genetically modify immune cells inside the body, an approach could ...

Gilead Sciences is accelerating its growth rate and Yeztugo might be another major blockbuster. GILD stock is still trading ...

The owner of the United States' largest pharmacy benefit manager (PBM) is declining to cover Gilead Sciences’ long-acting HIV ...

Market Catalysts Host Julie Hyman recaps some of the trending tickers on Thursday, Aug. 21, including Coty (COTY), Gilead ...

Gilead Sciences agreed to buy Interius BioTherapeutics, a privately held biotechnology company developing in-vivo CAR therapeutics, for $350 million. Gilead on Thursday said the deal complements the ...

CVS Health will not add Gilead Sciences' new HIV prevention drug to its commercial plans for now, despite the medicine's ...

Gilead, its investors, and AIDS activists have high hopes for Yeztugo. Approved in June for people at high risk of HIV, the ...

Gilead Sciences on Thursday reported flat second-quarter earnings on slightly higher revenue and raised its full-year financial outlook, citing better-than-expected sales of HIV drugs.

Gilead Sciences (NASDAQ:GILD) announced its second-quarter 2025 earnings and revised annual outlook after the market closed on Thursday. The HIV drug maker reported adjusted earnings of $2.01 per ...